GENEVA, SWITZERLAND / ACCESS WIRE / April 7, 2021 / RELIEF THERAPEUTICS Holding AG (SIX: RLF) (OTCQB: RLFTF) (“Reduction“or the”Firm“), a biopharmaceutical firm with its principal compound RLF-100TM (aviptadil) in superior scientific improvement to deal with respiratory issues induced by COVID-19, right now introduced the appointment of JJ Scherpbier of Sonsbeek Pharma Consultancy BV as a producing and provide chain marketing consultant efficient 1 April 2021. Mr. Scherpbier will help the back-up administration workforce in all actions associated to manufacturing and provide tasks throughout the corporate’s portfolio. Mr. Scherpbier will initially concentrate on establishing a provide chain in Reduction’s territory for ACER-001, a proprietary powder formulation of sodium phenylbutyrate (NaPB) designed to be each masked on the identical time style and quick launch for the therapy of urea cycle issues.
Raghuram (Ram) Selvaraju, President of the Reduction Council, stated: “I’m delighted to welcome Jan-Jaap to the rescue workforce as we diversify our portfolio and take the subsequent steps within the international improvement and commercialization of ACER-001. His expertise and his management in pharmaceutical improvement and GMP will present him with important help to the emergency administration workforce. “
Mr. Scherpbier is a extremely skilled pharmaceutical marketing consultant with over 25 years of experience in regulatory affairs, life cycle administration, pharmaceutical improvement and GMP. All through his profession, Mr. Scherpbier has labored carefully with the event, manufacturing and high quality capabilities by collaborating in actions reminiscent of know-how switch, troubleshooting, truth discovering and enchancment of BPF. Mr Scherpbier graduated as a pharmacist from the College of Groningen within the Netherlands and subsequently obtained an M.Sc. Diploma in Regulatory Affairs from the College of Wales.
“I sit up for getting began with Reduction to help manufacturing and provide tasks throughout their portfolio,” stated JJ Scherpbier, Emergency Manufacturing and Provide Chain Guide. “Specifically, I sit up for working carefully with the Reduction and Acer groups to ascertain the worldwide provide chain and manufacturing capabilities for the ACER-001. It’s thrilling to have the chance to play a job in advancing the potential of a drug that helps affected person adherence and will thus enhance their high quality of life. “
Reduction primarily focuses on drug-based scientific stage packages with a historical past of scientific trials and use in human sufferers or a robust scientific rationale. The lead drug candidate for Reduction RLF-100TM (aviptadil), an artificial type of vasoactive intestinal peptide (VIP), is in scientific testing in america for the therapy of respiratory failure as a result of COVID-19. As a part of its pipeline diversification technique, in March 2021, Reduction entered right into a collaboration and license settlement with Acer Therapeutics for the worldwide improvement and commercialization of ACER-001. ACER-001 is a proprietary, quick launch, masked powder formulation of sodium phenylbutyrate (NaPB) for the therapy of urea cycle issues and maple syrup urinary illness.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Trade beneath the image RLF and listed in america on OTCQB beneath the image RLFTF. For extra data go to www.relieftherapeutics.com.
observe us on LinkedIn.
RELIEF THERAPEUTICS Holding AG
Raghuram (Ram) Selvaraju, Ph.D., MBA
President of the council
E mail: [email protected]
|FOR MEDIA / INVESTOR REQUESTS:
MC Companies AG
Anne Hennecke / Brittney Sojeva
Cellphone: +49 (0) 211-529-252-14
E mail: [email protected]
Warning: This communication expressly or implicitly incorporates sure forward-looking statements regarding RELIEF THERAPEUTICS Holding AG and its actions. The outcomes reported right here could or is probably not indicative of future and bigger scientific trial outcomes for ACER-001 for the therapy of UCDs and MSUDs, or whether or not ongoing scientific trials of Reduction’s lead compound, RLF-100 (TM) (aviptadil) in superior scientific improvement to deal with respiratory impairment as a result of COVID-19, will likely be profitable. Such statements contain sure dangers, uncertainties and different identified and unknown components, which may trigger the precise outcomes, monetary place, efficiency or achievements of RELIEF THERAPEUTICS Holding AG to be materially totally different from any outcomes, efficiency or achievements. futures expressed or implied by such prospect. – forward-looking statements. RELIEF THERAPEUTICS Holding AG is offering this communication as of this date and doesn’t undertake to replace any forward-looking statements contained on this doc on account of new data, future occasions or in any other case.
SOURCE: Reduction Therapeutics Holdings AG
See the supply model on accesswire.com: